Q2 2022 13F Holders as of 6/30/2022
-
Type / Class
-
Equity / Common Stock, par value $0.001 par value per share
-
Shares outstanding
-
73.8M
-
Number of holders
-
102
-
Total 13F shares, excl. options
-
24.2M
-
Shares change
-
+1.89M
-
Total reported value, excl. options
-
$460M
-
Value change
-
+$33.7M
-
Put/Call ratio
-
0.82
-
Number of buys
-
61
-
Number of sells
-
-32
-
Price
-
$18.99
Significant Holders of RELMADA THERAPEUTICS, INC. - Common Stock, par value $0.001 par value per share (RLMD) as of Q2 2022
142 filings reported holding RLMD - RELMADA THERAPEUTICS, INC. - Common Stock, par value $0.001 par value per share as of Q2 2022.
RELMADA THERAPEUTICS, INC. - Common Stock, par value $0.001 par value per share (RLMD) has 102 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 24.2M shares
of 73.8M outstanding shares and own 32.84% of the company stock.
Largest 10 shareholders include RTW INVESTMENTS, LP (2.64M shares), VR Adviser, LLC (2.27M shares), BlackRock Inc. (2.15M shares), RA CAPITAL MANAGEMENT, L.P. (2M shares), BVF INC/IL (1.66M shares), VANGUARD GROUP INC (1.42M shares), Point72 Asset Management, L.P. (1.27M shares), COWEN AND COMPANY, LLC (1.07M shares), CITADEL ADVISORS LLC (947K shares), and Vivo Capital, LLC (706K shares).
This table shows the top 102 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.